Global Blood Therapeutics Appoints Ted W. Love, M.D., to the Company's Board of Directors

SAN FRANCISCO--(BUSINESS WIRE)--Global Blood Therapeutics, a product-focused company developing novel, orally-available therapeutics for chronic blood diseases, today announced the appointment of Ted W. Love, M.D., to the company's board of directors. Dr. Love most recently served as executive vice president, research and development and technical operations at Onyx Pharmaceuticals.

"Ted is a seasoned industry leader with extensive drug development experience and an impressive track record of moving drug candidates through the clinic to approval," said Mark A. Goldsmith, M.D., Ph.D., chief executive officer of Global Blood Therapeutics and partner at Third Rock Ventures. "We are pleased to welcome him to the Global Blood Therapeutics team as we continue to advance our pipeline of preclinical programs focused on blood diseases, including sickle cell disease. We fully expect Ted to have significant impact in helping us fulfill our vision of changing the treatment paradigm for chronic blood diseases."

Dr. Love has more than 20 years of broad leadership and management experience in the pharmaceutical industry. In his most recent position at Onyx, he played an instrumental role in initiating and completing several of Onyx's first Phase 3 clinical trials. Prior to Onyx, Dr. Love served as president, chief executive officer and chairman of Nuvelo, Inc., where he led growth of the company to a market capitalization of $1 billion, and previously served as senior vice president, development at Theravance, Inc. Earlier in his career, Dr. Love held roles of increasing responsibility in medical affairs and product development at Genentech. As vice president, product development, Dr. Love oversaw the development strategy and execution leading to approvals of Rituxan, Herceptin, Xolair, TNKase, Raptiva and Avastin. Dr. Love has served as a consultant in medicine at Massachusetts's General Hospital in the department of cardiology. Dr. Love currently sits on the board of directors of Santarus, Amicus Therapeutics, Oncothryeon, Avillion and KaloBios. He holds a B.A. in molecular biology from Haverford College and an M.D. from Yale Medical School.

"I have a longstanding interest in trying to solve sickle cell disease and other chronic blood diseases that are inadequately served," said Dr. Love. "The current standard of care for sickle cell disease focuses on treating acute symptoms, despite the chronic, underlying disease process that causes progressive damage to the vital organs. What I find most compelling about Global Blood Therapeutics' approach is its emphasis on addressing fundamental mechanisms of disease, not just the symptoms, and I look forward to helping advance these potentially breakthrough therapeutics."

About Global Blood Therapeutics

Global Blood Therapeutics is a product-focused company developing novel, orally-available therapeutics for chronic blood diseases. The Company is addressing severe, non-malignant blood-based diseases for which there are currently no effective cures and only limited therapeutic options. Global Blood Therapeutics is focused on the critical need for therapeutics that address the underlying causes of blood diseases, not just the symptoms. The Company's extensive drug discovery capabilities — combining world-class medicinal chemistry with deep expertise in blood biology — are driving its product pipeline of mechanism-based therapeutics, including programs in sickle cell disease and hereditary angioedema. Global Blood Therapeutics is a private company launched in 2012 by Third Rock Ventures with an experienced leadership team and renowned scientific founders. For more information, please visit www.globalbloodtx.com

Contacts

Pure Communications
Alicia Gronneberg, 910-239-5036
[email protected]

 

Suggested Articles

Biogen stunned the biotech world Tuesday when it said it would file aducanumab for approval. Now that the dust has settled, what are analysts saying?

Biocytogen uses chromosome engineering for the in situ replacement of mouse antibody genes with the human counterparts.

Eli Lilly is canning the lead program for the crown jewel of its $1.6 billion Armo buyout after the drug put up a poor showing in pancreatic cancer.